“It's all about getting the dose right ". As proclaimed by native Amazonian tribes who used the plant extract ‘Curare’ whilst hunting to stun their prey. The dosage had to be small enough to fit onto an arrowhead but still remain effective.
Clinical pharmacology also revolves around dosage. In fact, during the drug development process, it is essential to strive for optimal effectiveness and safety for the patient.

Taking these boundaries into account, Curare provides strategic advice to assist in the successful design of drug development programs. From the non-clinical phase to the clinical Proof-of-Concept up to registration. At Curare we believe an effective clinical program is built on relevant translatable in vitro and in vivo pharmacology data generated at the laboratory bench and from animal models. Our focus is on mode of action deconvolution in conjunction with the identification of (non)clinical translatable biomarkers, boosting the success of a clinical development program plan. We are agnostic to therapeutic modalities, whether it refers to small or large molecules, biologics, vaccines, antibodies, peptides, gene cell-based therapy.

Areas of expertise: Strategic drug development, Clinical pharmacology, Translational science.

Curare

Tonke van Bragt

This department specializes in guiding and supporting the early stages of clinical research and development.

Early Clinical Development

This department focuses on the design and implementation of clinical trials and pharmacological research to evaluate the efficacy and safety of new treatments.

Curare

Org chart

Teams

Early Clinical Development

Clinical Development

Offices